Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 1/20 | 0.41 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.41 |
| ▸ | NOD1 | Q9Y239 | 6/20 | 0.39 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.37 |
| ▸ | MME | P08473 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17164976 | 0.94 | HDAC2 (0.39) | HDAC2KMT2APOLBL3MBTL1 | |
| SCHEMBL17164977 | 0.94 | HDAC2 (0.39) | HDAC2KMT2APOLBL3MBTL1 | |
| SCHEMBL17164973 | 0.91 | NOD1 (0.45) | NOD1HDAC2FOLH1KMT2A | |
| SCHEMBL17164972 | 0.91 | NOD1 (0.45) | NOD1HDAC2FOLH1KMT2A | |
| SCHEMBL17164986 | 0.86 | GNPAT (0.43) | NOD1FOLH1 | |
| SCHEMBL17164985 | 0.86 | GNPAT (0.43) | NOD1FOLH1 | |
| SCHEMBL18735087 | 0.86 | HDAC2 (0.36) | ITGB1ITGA4HDAC2KMT2APOLB | |
| SCHEMBL18734801 | 0.86 | HDAC2 (0.36) | ITGB1ITGA4HDAC2KMT2APOLB | |
| SCHEMBL18735203 | 0.85 | ITGB1 (0.35) | ITGB1ITGA4HDAC2POLB | |
| SCHEMBL18734973 | 0.80 | NOD1 (0.41) | NOD1FOLH1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3391941-B1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Abliva Ab (SE) | 2023-06-07 | — | — | EP | disclosed |
| US-20210401792-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | Abliva Ab (SE) | 2021-12-30 | — | — | US | disclosed |
| US-11147789-B2 | Cell-permeable succinate compounds | Abliva Ab (SE) | 2021-10-19 | — | — | US | disclosed |
| US-10307389-B2 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation | NEUROVIVE PHARMACEUTICAL AB (SE) | 2019-06-04 | — | — | US | disclosed |
| EP-3129016-B1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | NEUROVIVE PHARMACEUTICAL AB (SE) | 2018-06-06 | — | — | EP | disclosed |
| US-20170105961-A1 | Novel Cell-Permeable Succinate Compounds | Abliva Ab (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170105961-A1 | Novel Cell-Permeable Succinate Compounds | Abliva Ab (SE) | 2017-04-20 | — | — | US | disclosed |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | Abliva Ab (SE) | 2017-04-13 | — | — | US | disclosed |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | Abliva Ab (SE) | 2017-04-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170105961-A1 | Novel Cell-Permeable Succinate Compounds | SLC25A1, SLC25A11, CS | ITGB1 3799/4885ITGA4 4365/4885NOD1 4482/4885 |
| US-11147789-B2 | Cell-permeable succinate compounds | SLC25A1, SLC25A11, SLC25A21 | ITGB1 3610/4885ITGA4 4294/4885NOD1 4463/4885 |
| US-20170100359-A1 | Succinate Prodrugs for Use in the Treatment of Lactic Acidosis or Drug-Induced Side-Effects Due to Complex I-Related Impairment of Mitochondrial Oxidative Phosphorylation | CS, MDH2, SLC25A11 | ITGB1 4180/4885ITGA4 4545/4885NOD1 4339/4885 |
| US-10307389-B2 | Succinate prodrugs for use in the treatment of lactic acidosis or drug-induced side-effects due to Complex I-related impairment of mitochondrial oxidative phosphorylation | CS, MDH2, SLC25A11 | ITGB1 4180/4885ITGA4 4545/4885NOD1 4339/4885 |
| US-20210401792-A1 | NOVEL CELL-PERMEABLE SUCCINATE COMPOUNDS | SLC25A1, SLC25A11, CS | ITGB1 3856/4885ITGA4 4359/4885NOD1 4463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.